Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age

Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial

(2012) Monika E. Hegi et al.   ACTA NEUROPATHOLOGICA

Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma

(2012) Dominik Sturm et al.   CANCER CELL

Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome

(2012) Y. Wang et al.   NEURO-ONCOLOGY

Correlation of IDH1 Mutation with Clinicopathologic Factors and Prognosis in Primary Glioblastoma: A Report of 118 Patients from China

(2012) Wei Yan et al.   PLoS One

Mutated IDH1 Is a Favorable Prognostic Factor for Type 2 Gliomatosis Cerebri

(2011) Mi Jung Kwon et al.   BRAIN PATHOLOGY

Molecular and clinical analysis of glioblastoma with an oligodendroglial component (GBMO)

(2011) Hideo Nakamura et al.   Brain Tumor Pathology

IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma

(2011) Qi SongTao et al.   CANCER SCIENCE

Glioblastomas with oligodendroglial component-common origin of the different histological parts and genetic subclassification

(2011) Barbara Klink et al.   CELLULAR ONCOLOGY

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

(2010) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma

(2009) Alba A. Brandes et al.   CANCER

Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas

(2009) Marc Sanson et al.   JOURNAL OF CLINICAL ONCOLOGY

Cerebral glioblastoma with oligodendrogliomal component: analysis of 36 cases

(2009) Maurizio Salvati et al.   JOURNAL OF NEURO-ONCOLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Galectin-3: A useful biomarker for differential diagnosis of brain tumors

(2008) Sung-Hye Park et al.   NEUROPATHOLOGY

Glioblastomas: correlation between oligodendroglial components, genetic abnormalities, and prognosis

(2008) Luciana Wernersbach Pinto et al.   VIRCHOWS ARCHIV